| Autor: |
Springfeld, Christoph, Wiecha, Christiane, Kunzmann, Romy, Heger, Ulrike, Weichert, Wilko, Langer, Rupert, Stange, Annika, Blank, Susanne, Sisic, Leila, Schmidt, Thomas, Lordick, Florian, Jäger, Dirk, Grenacher, Lars, Bruckner, Tom, Büchler, Markus, Ott, Katja |
| Zdroj: |
Annals of Surgical Oncology: An Oncology Journal for Surgeons; Dec2015 Supplement, Vol. 22, p905-914, 10p |
| Abstrakt: |
Background: Perioperative chemotherapy improves survival in patients with advanced esophagogastric cancer, but the optimal treatment regimen remains unclear. More intensive chemotherapy may improve outcome, but also increase toxicity and complications. Methods: A total of 843 patients were included in this retrospective study and stratified in 4 groups: doublet therapy with cisplatin or oxaliplatin and 5-fluorouracil (groups A/B) or triplet therapy with additional epirubicin or taxane (groups C/D). The influence of the different neoadjuvant chemotherapy regimens on response, prognosis, and complications was assessed. Results: Clinical and pathological response were associated with longer overall survival (OS; p < 0.001). No significant differences regarding response or OS were found, but there was a trend toward better outcome in group D (taxane-containing triplet). In the subgroup of 669 patients with adenocarcinomas of the esophagogastric junction (AEG), patients who had received taxane-containing regimens had a significantly longer OS ( p = 0.037), but taxane use was not an independent factor in multivariate analysis. Triple therapy with taxanes did not result in a higher complication rate or postoperative mortality. Conclusions: Although no superior neoadjuvant chemotherapy regimen was identified for patients with esophagogastric adenocarcinoma, taxane-containing regimens should be further investigated in randomized trials, especially in patients with AEG tumors. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink